ClinicalTrials.gg
CompletedNCT07058688SPPN-ADUpdated Oct 29, 2026

A Study of NTRX-07 in Participants With Alzheimer's Disease

A Phase 2 interventional study of NTRX-07 and Placebo in Alzheimer Disease and Mild Cognitive Impairment, sponsored by NeuroTherapia, Inc.. Completed at 6 sites in 3 countries. Open to participants aged 65 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by NeuroTherapia, Inc. · Phase 2, Interventional, and Treatment

How we know

Updated Oct 29, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
65 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 70 studies in Alzheimer Disease with a site in Czechia — 14 open to participants now, 18 under way, 8 of them phase 3. Alzheimer Disease · Czechia.

Enrollment
65th of 68
48 · median 434
Started
2025
with 6 others
Phase 2
25 of 70
2 open now
Registered
60th of 70
by date

Among the 70 studies in Alzheimer Disease with a site in Czechia, this one is the 65th largest by enrollment of the 68 interventional ones that give a count, is one of 7 that started in 2025, is one of 25 in phase 2, and was the 60th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

14 of the 70 studies in Alzheimer Disease with a site in Czechia are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 65 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Alzheimer Disease with a site in Czechia, or all of them as a file.
02

Study summary

  1. Study Overview NeuroTherapia Inc. is conducting a clinical study to explore the safety and effects of a new drug called NTRX- 07. This drug targets people with mild cognitive impairment (MCI) or mild to moderate Alzheimer's disease (AD). The study's primary focus is on safety and how the drug interacts with the body over a short-term period of 28 days. This research is important as it aims to find new ways to manage symptoms and slow the progression of AD.
  2. Key Objectives Primary Objective:

    • To assess the safety and tolerability of NTRX-07 in patients with AD.
    • Safety and tolerability will be measured by monitoring any side effects or adverse events in participants during and after the treatment period.

    Secondary Objective:

    • To study how NTRX-07 is processed by the body, including how it is absorbed, distributed, metabolized, and eliminated.
    • This includes measuring the drug levels in the blood and cerebrospinal fluid (CSF) over time.
  3. Study Design • Type of Study:

    o A randomized, double-masked, placebo-controlled study. "Randomized" means participants are randomly assigned to receive either the actual drug (NTRX-07) or a placebo (an inactive substance). "Double-masked" indicates that neither the participants nor the researchers know who receives the real drug or the placebo, reducing bias and ensuring objective results.

    • Participants:
    • 48 individuals with MCI or mild to moderate AD.

      • Treatment Groups:
    • Participants will be split into two groups: 24 will receive NTRX-07, and 24 will receive a placebo.

      • Duration:
    • The study will last up to 7-10 weeks for each participant, including a 28-day period during which they take the drug or placebo daily.
  4. Study Procedures

    • Screening Period:
    • Before starting the treatment, participants will undergo a screening period of up to 45 days. During this time, they will have tests to confirm their eligibility, including physical exams, blood tests, cognitive assessments, and brain imaging (MRI).

      • Treatment Period (28 days):
    • Participants will take the study drug or placebo daily for 28 days. During this period, they will visit the study center for evaluations, including safety checks, cognitive tests, blood and CSF sampling, and EEG tests (to measure brain activity).

      • Follow-Up:
    • After the treatment period, participants will have a follow-up visit 7 days later for final safety assessments.
  5. Safety Monitoring and Assessments

    • The study's primary focus is on safety. Researchers will monitor participants closely for any adverse events, such as side effects, throughout the study.
    • Safety assessments will include monitoring vital signs (blood pressure, heart rate, temperature), conducting laboratory tests (blood and urine analysis), performing physical examinations, and using electrocardiograms (ECGs) to monitor heart health.
  6. Exploratory Assessments

    • Although this study primarily focuses on safety, researchers will also conduct exploratory assessments to observe any potential positive effects of NTRX-07 on brain function and symptoms of AD. These will include:

    o Cognitive Testing:

    • Standard tests like the AD Assessment Scale-Cognitive Subscale (ADAS-cog) and the Mini-Mental State Examination (MMSE) will be used to evaluate any changes in cognitive function.

      o Brain Imaging:

    • MRI scans will help assess changes in brain structure and inflammation.

      o Biomarkers:

    • Blood and CSF samples will be analyzed for specific biomarkers related to inflammation, brain health, and AD progression.
  7. Eligibility Criteria

    • Inclusion Criteria:

      • Individuals aged 65-88 with a confirmed diagnosis of MCI or mild to moderate AD.
      • Must have a caregiver who can assist with the study requirements.
      • Must be able to undergo specific procedures like MRI scans and CSF sampling.
    • Exclusion Criteria:

      • Individuals with other significant health conditions or history of neurological disorders other than AD.
      • Those currently participating in another clinical trial or have certain medication restrictions.
  8. Importance of the Study AD is a progressive condition that affects memory, thinking, and behavior. Current treatments only manage symptoms temporarily, and there is an need for new therapies. NTRX-07 is a novel drug that has shown promise in animal studies, potentially reducing brain inflammation, clearing harmful proteins, and improving memory and learning. This study is an essential step toward understanding if NTRX-07 can offer a safe and effective treatment option for people with AD.
  9. Summary This clinical trial is designed to test the safety and processing of a new drug, NTRX-07, in people with MCI or mild to moderate AD. Participants will be carefully monitored for any side effects while researchers also gather data on the drug's impact on brain function. If successful, this study could lead to more advanced trials and, ultimately, a new treatment option for those affected by AD.
03

Conditions studied

  • Alzheimer Disease
  • Mild Cognitive Impairment

Keywords

  • clinical pharmacology
  • neuroinflammation
04

Who can participate

Ages eligible
65 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be 65-80 years of age inclusive, at the time of signing the .
  2. Clinical Dementia Rating (CDR) of 0.5 - 2.0; and education-adjusted Logical Memory II scores consistent with MCI or mild to moderate AD (\<1.5 SD below mean cutoff). 12-26
  3. pTau 217 consistent with AD, or recent amyloid test panel within 2 years. The test must be after any previous participation in an anti-amyloid MAB trial.
  4. Participants who have been in a previous amyloid-directed MAB study must have a negative ARIA report after the study.
  5. Confirmed medical documentation of AD symptoms onset at age 60 or later.
  6. No active depression and a Geriatric Depression Score of \< 6.
  7. No change in acetylcholinesterase inhibitors or memantine for the previous six months and is not expected to start an acetylcholinesterase inhibitor during the duration of the study.
  8. Living at home, with a reliable caregiver who sees them at least 3 times/week for 10 hours or more and can oversee the administration of the study drug.
  9. Provide written informed consent and willingness as documented by a signed informed consent form; responsible caregiver must also provide written consent.
  10. Body weight within 55-110 kg and (BMI) within the range 18-35 kg/m2 (inclusive)
  11. Male or Female • Male participants: Male participants are eligible to participate if they agree to the following during the intervention period and for at least 90 days, after the last dose of study intervention:

Refrain from donating sperm PLUS, either:

Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent ba sis) and agree to remain abstinent.

OR

  • Agree to use a male condom and should also be advised of the benefit for a female partner to use a highly effective method of as a condom may break or leak when having sexual intercourse with a woman of who is not currently pregnant.
  • Agree to use a male condom when engaging in any activity that allows for passage of ejaculate to another person.

    • Female participants: Must be a woman of nonchildbearing potential (WONCBP) (at least two years or surgically sterile).

Exclusion criteria

Exclusion Criteria

  1. Reported history or presence of history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data. Participants with stable, well-controlled conditions may be accepted upon review by the investigator and sponsor.
  2. Change of more than 2 points from screening to baseline MMSE, or discrepancy in disease classification between MMSE, and Trail Making test.
  3. Diagnosis of a dementia-related CNS disease other than AD (eg, Parkinson's Disease, Huntington's Disease, frontotemporal dementia, multi-infarct dementia, dementia with Lewy bodies, normal pressure hydrocephalus)
  4. Cannot tolerate spinal puncture procedure for cerebral spinal fluid (CSF).
  5. Anticoagulation therapy that would contraindicate spinal puncture procedure for cerebral spinal fluid (CSF).
  6. Any to MRI (per facility standard of care).
  7. Major structural brain disease by reported history or chart review (e.g., ischemic infarcts, subdural hematoma, hemorrhage, hydrocephalus, brain tumors, multiple subcortical ischemic lesions, severe mi- microangiopathic disease, volume loss disproportionate for age or a single lesion in a critical region e.g., thalamus, hippocampus).
  8. Findings on MRI demonstrating intracranial pathology as an alternative cause for cognitive impairment
  9. Any other reported history of central nervous system (CNS) trauma (e.g., contusion), or infections (e.g., [HIV], syphilis), that present active or residual effects on cognitive function.
  10. Reported history of seizures, with the exception of childhood febrile seizures or metabolic seizures where the underlying etiology has resolved, and the participant has been seizure-free without treatment for at least 2 years.
  11. disorders, active infections or other disorders, including the use of , that may affect the subject's immune system.
  12. Reported current or chronic history of clinically significant liver disease. This includes but is not limited to hepatitis virus infections, drug- or alcohol-related liver disease, nonalcoholic steatohepatitis, autoimmune hepatitis, hemochromatosis, Wilson's disease, α-1 antitrypsin deficiency, primary biliary cholangitis, primary sclerosing cholangitis, or any other liver disease considered clinically significant by the investigator.
  13. Reported hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) that are deemed clinically significant by the PI or medical monitor.
  14. Abnormal TSH, fT3 or fT4 at baseline screening. Subjects with known hypothyroidism or hyperthyroidism should be stable on treatment for 6 months prior to starting study and not anticipated to require any type of dose adjustment during the course of the study.
  15. Reside in a nursing home or assisted care facility with the need for direct continuous medical care and nursing supervision. Participant may reside in such facilities provided continuous direct medical care is not required.
  16. Subjects who require close or continual monitoring for self care or basic activities of daily living.
  17. Subjects with history of psychiatric conditions such as schizophrenia and or bipolar disorder
  18. Any reported history from the patient, family, or on supplied chart re- view or current suicide risk
  19. Patients may continue prior concomitant medications at the same sta ble dose. Drugs with potential interactions are detailed in the investi gator's brochure. Participants receiving drugs with strong interactions should be excluded where the drug in question cannot be safely stopped for an appropriate pre-study and until 7 days after the last dose of study medication (completion of the post-study safety visit).
  20. Reported treatment with biological agents in the 3 months prior to dosing in this study, or within 5 half-lives of the biological agent prior to dosing..
  21. Current enrollment or past participation within the last 30 days before signing of consent in any other clinical study involving an investiga- tional study intervention.
  22. Clinical laboratory findings outside the normal range and determined by the investigator or medical monitor to be clinically significant. These include but are not limited to:

    1. (ALT) or aspartate transaminase (AST) >1.5 x (ULN)
    2. Total >1.5 x ULN (isolated bilirubin >1.5 x ULN is acceptable if total bilirubin is fractionated and direct bilirubin \<35%)
    3. >450 msec for male participants or >470 msec for female participants
    4. Positive drug/alcohol screen
  23. Reported sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study
  24. Reported regular use of known drugs of abuse within the past 3 years.
  25. Inability to withhold CNS medications (e.g., benzodiazepines, stimulants) for 3 half-lives of the drug prior to cognitive testing and EEG administration.
  26. Presence of any contraindication to venous blood sampling for pharmacokinetic analyses.
  27. Positive SARS-CoV-2 test, hepatitis panel (including sur face antigen [HBsAg] or virus antibody [anti-HCV]), a positive HIV antibody screen or positive syphilis test
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    QD Dosing

    NTRX-07 90 mg as two 45 mg tablets administered orally once per day

    Drug: NTRX-07

  • Placebo comparator
    Placebo

    Two tablets matching the Experimental treatment administered orally once per day

    Drug: Placebo

Interventions

  • DrugNTRX-07

    Orally administered CB2 agonist

    Also known as: MDA7

  • DrugPlacebo

    Inactive matched comparator

06

What researchers measure

Primary outcomes

  1. Adverse event incidence in NTRX-07 treated participants

    Incidence of adverse events during the trial, compared between the active treatment and placebo groups, through study completion, about 6 weeks.

    Time frame: From date of randomization through final study visit, up to 6 weeks.

Secondary outcomes

  1. Plasma Pharmacokinetics of NTRX-07 - Area under the curve

    Mean area under the curve determined by plasma levels from time zero to 10 hrs post-dose

    Time frame: First day of dosing and Day 28

  2. Plasma Pharmacokinetics of NTRX-07 - Maximum concentration

    Mean Maximum concentration determined by plasma levels from time zero to to 10 hrs post-dose

    Time frame: First day of dosing and Day 28

  3. Cerebrospinal fluid Pharmacokinetics of NTRX-07 - concentration compared to simultaneous plasma levels

    Mean ratio of CSF concentration to plasma levels at 90 minutes post-dose

    Time frame: Day 28

  4. Change in ADAS-cog in treated participants from baseline

    Time frame: Baseline and Day 28

  5. Change in MMSE in treated participants from baseline

    Time frame: Baseline and day 28.

  6. Change in Free-water by MRI in treated participants

    Free water determined by MRI as a measure of neuroinflammation

    Time frame: Baseline and last day of dosing + up to 5 days

  7. Change in Cortical Disarray Measurement (CDM) determined by MRI in treated subjects

    Cortical Disarray Measurement as measure of neuronal interconnectivity

    Time frame: Baseline and last day of dosing + up to 5 days

  8. Change in Quantitative EEG in treated participants

    32 lead EEG; absolute power and relative power in the different frequency bands, 10 min eyes shut followed by 10 min eyes open. EEG processing involves the computation of the spectra of artifact-free segments. The Hanning window is used, and the FFT algorithm is analyzed using Matlab scripts. The AUC of spectrum segments provides estimations of power in each frequency band of interest. Absolute powers and relative powers are provided for each band. For each band, relative power is the absolute power divided by the power of the total band.

    Time frame: Baseline and Day 28

  9. Change in Quantitative EEG p-300 evoked response in treated participants

    The P300 wave is an evoked potential that reflects the decision-making process in the cerebral cortex in a situation of cognitive task. It is obtained by repeated stimulations with two types of auditory stimuli: a group of stimuli constituting the background (stimuli called "standard" or "frequent"), against different stimuli which are less frequent (stimuli named "odd" or "rare" or "deviant"). The P300 wave is characterized by a positive deflection occurring approximately 300 ms after odd stimuli. The standard stimulus is a 500Hz sound, and the oddball stimulus is a 2000Hz sound. Stimuli are presented through calibrated headphone in a pseudo randomized order. The inter-stimulus interval is randomized between 1200 and 1900ms to avoid anticipation. Oddball makes up 15% of presentations.

    Time frame: Baseline and Day 28

  10. Change in Plasma biomarkers in treated participants

    High-sensitivity C-Reactive Protein (hsCRP), HbA1, erythrocyte sedimentation rate (ESR), TNF-a, IL-1b, IL-6, IL-2, YKL- 40, sTREM2, Abeta40, Abeta42, ptau217

    Time frame: Baseline and Day 28

  11. Change in CSF biomarkers in treated participants

    TNF-a, IL-1b, IL-6, IL-2, YKL- 40, sTREM2, Abeta40, Abeta42, ptau217, Neurogranin, synaptotagmin-1, NfL, GFAP

    Time frame: Baseline and Day 28

07

Study locations

6 sites
  • Neuro Health Centrum s.r.o.
    Brno, 628 00, Czechia
  • Neuropsychiatrie s.r.o.
    Prague, 160 00, Czechia
  • Semmelweis University
    Budapest, 1083, Hungary
  • Semmelweis University
    Budapest, 1145, Hungary
  • Szpital Uniwersytecki W Krakowie
    Krakow, 30-688, Poland
  • Wrocławskie Centrum Alzheimerowskie
    Wroclaw, 53-659, Poland
08

References and documents

Individual participant data

Plan to share: Yes — To be determined. Key elements of safety and biomarker endpoints will be shared.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: 12 months after study closure and publication in a peer-reviewed journal. Information will be maintained for at least 3 years.

Access criteria: A central publically available repository will be used. The repository will manage data access and permissions. Individual data points with a limited set of patient identifiers will be provided. GDPR regulations will be observed.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Feb 2026, 11 months.

Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 11 months is below that.

Counting every sponsor, half of 259 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Dec 2025 → Feb 2026 and completion Jun 2026 → Mar 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2025
First posted
Jul 10, 2025
StartActual
Mar 1, 2025
Primary completionActual
Feb 15, 2026was Dec 2025
CompletionActual
Mar 3, 2026was Jun 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 29, 2026
Primary completion
Dec 31, 2025→Feb 15, 2026 (actual)
Oct 29, 2026
Study completion
Jun 30, 2026→Mar 3, 2026 (actual)
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Recruiting→Completed
    Primary completion Dec 31, 2025→Feb 15, 2026 (now actual)
    Study completion Jun 30, 2026→Mar 3, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07058688
Lead sponsor
NeuroTherapia, Inc.
Collaborators
Cruint Global Consulting Pte Ltd, Firalis SA, Pharma-Regist Kft.
Responsible party
Sponsor
First posted
Jul 10, 2025
Start date
Mar 1, 2025
Primary completion
Feb 15, 2026
Completion
Mar 3, 2026
Last update
Oct 29, 2026

Study contacts

Joseph F Foss, MD
study director · NeuroTherapia, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion